Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network will create an ethnically diverse single-cell atlas of the response to commonly used vaccines such as flu vaccines with a focus on responses in lymph nodes.

© Shutterstock/Numstocker

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells.

In partnership with Imperial College London and the Uganda Virus Research Institute, the Lymph nodE single-cell Genomics AnCestrY (LEGACY) Network aims to understand and ultimately to predict how humans respond to vaccination at a single-cell level, whilst simultaneously creating universally available on-line materials as resources for further research.

Prof Hashem Koohy, a Co-PI of the project and an Associate Professor of systems immunology at the MRC Human Immunology Unit said: ‘The LEGACY Network project is a very exciting multi institutional and multidisciplinary effort that aims to provide deeper insights into vaccine-induced differential immune response at single cell level in an ethnically diverse population.

‘The existing single cell data that build our prior knowledge of human diseases are mainly biased by European ancestry. The LEGACY Network provides an opportunity to study differential immune response to vaccines in the light of diversity and ancestry.’

Such projects have the potential to significantly advance understandings of how vaccines stimulate immunity across ethnicities and provide new insights for future efforts in vaccine design.

The resources created by the LEGACY Network will serve as a foundation for overcoming differences in vaccine efficacy associated with ancestry, and for accelerating and promoting equity in vaccine research.

Read the full news item on the University of Oxford’s website.

Similar stories

Jan Bornschein receives MRC Clinical Academic Research Partnership (CARP) Award

Dr Bornschein will join the Simmons Group for a project developing strategies to identify patients at high risk of gastritis/gastric cancer.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

MRC HIU research at the 2022 Grand Challenges Annual Meeting

Nicole Stoffel and Michael Zimmerman presented at the 18th Grand Challenges Annual Meeting which took place in Brussels, Belgium on 23rd- 26th October 2022.

2022 RDM Graduate Prize Winners

This year's RDM winners are Edward Jenkins, Antje Rottner, and Akshay Shah.

New UK research consortium formed to tackle monkeypox outbreak

Investigation of the T cell responses against monkeypox virus will be led by Prof. Tao Dong at the CAMS-Oxford Institute and MRC Human Immunology Unit.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.